Page last updated: 2024-10-24

negative regulation of RNA polymerase II transcription preinitiation complex assembly

Definition

Target type: biologicalprocess

Any process that stops, prevents, or reduces the frequency, rate or extent of RNA polymerase II transcriptional preinitiation complex assembly. [GOC:go_curators]

Negative regulation of RNA polymerase II transcription preinitiation complex assembly is a crucial process that controls the initiation of gene transcription by RNA polymerase II. This process involves a complex interplay of various regulatory factors that act to inhibit the formation of the preinitiation complex (PIC), which is essential for the recruitment of RNA polymerase II to the promoter region of a gene and the initiation of transcription.

The PIC is a multi-protein complex that assembles at the promoter region of a gene and serves as a platform for the initiation of transcription. It is composed of RNA polymerase II and a number of general transcription factors (GTFs), including TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. The assembly of the PIC is a highly regulated process, and a number of factors can influence its formation, including the presence of specific DNA sequences, chromatin modifications, and the binding of regulatory proteins.

Negative regulation of PIC assembly is a critical mechanism for controlling gene expression. This regulation ensures that genes are only transcribed when necessary and that transcription is appropriately coordinated with cellular needs. A number of mechanisms can contribute to the negative regulation of PIC assembly, including:

1. **Competition for binding sites:** Certain regulatory proteins can bind to the same DNA sequences as the GTFs, effectively blocking their access and inhibiting PIC assembly.
2. **Chromatin modifications:** Modifications to chromatin structure, such as methylation or acetylation of histones, can influence the accessibility of the DNA to transcription factors and thus regulate PIC assembly.
3. **Recruitment of repressor proteins:** Repressor proteins can directly bind to the PIC components, interfering with their assembly or activity.
4. **Post-translational modifications of GTFs:** Modifications like phosphorylation or ubiquitination can alter the activity or stability of GTFs, impacting PIC assembly.

Overall, the negative regulation of RNA polymerase II transcription preinitiation complex assembly is a complex and multifaceted process that plays a critical role in controlling gene expression. This regulation ensures that gene transcription is tightly controlled, allowing for the appropriate response to various cellular cues and environmental changes.'
"

Proteins (3)

ProteinDefinitionTaxonomy
Thyroid hormone receptor alphaA thyroid hormone receptor alpha that is encoded in the genome of chicken. [OMA:P04625, PRO:DNx]Gallus gallus (chicken)
Thyroid hormone receptor alphaA thyroid hormone receptor alpha that is encoded in the genome of human. [PRO:HJD, UniProtKB:P10827]Homo sapiens (human)
High mobility group protein B1A high mobility group protein B1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09429]Homo sapiens (human)

Compounds (23)

CompoundDefinitionClassesRoles
salicylic acidScalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
amiodaroneamiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound
cardiovascular drug
diflunisaldiflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.

Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.
monohydroxybenzoic acid;
organofluorine compound
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
3,3',5-triiodothyroacetic acidtiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome.
3,3',5-triiodothyropropionic acidaromatic ether
thyroxinethyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.

Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine;
thyroxine zwitterion
antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
triiodothyronine3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.

Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine
human metabolite;
mouse metabolite;
thyroid hormone
glycyrrhizic acidglycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin
EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
mifepristoneMifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound
abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
tetraiodothyroacetic acid3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'.

tetraiodothyroacetic acid: RN given refers to parent cpd; structure
2-halophenol;
aromatic ether;
iodophenol;
monocarboxylic acid
apoptosis inducer;
human metabolite;
thyroid hormone
desethylamiodaronedesethylamiodarone: metabolite of amiodarone; structure given in first sourcearomatic ketone
3,5-dimethyl-3'-isopropyl-l-thyronine3,5-dimethyl-3'-isopropyl-L-thyronine: RN given refers to (L)-isomer
di-n-desethylamiodaronedi-N-desethylamiodarone: amiodarone metabolite in dogs; structure given in first source
methotrexatedicarboxylic acid;
monocarboxylic acid amide;
pteridines
abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
pregna-4,17-diene-3,16-dionepregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor3-hydroxy steroidandrogen
gc 1 compoundGC 1 compound: structure in first sourcediarylmethane
kb 141KB 141: an anticholesteremic agent; structure in first source
kb 130015KB 130015: structure in first source
cgs 23425CGS 23425: structure given in first source
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid: a thyroid receptor beta1 agonist; structure in first source
kb 21153-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid: a thyroid hormone receptor agonist with anticholesteremic activity
fg-4592roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH).

roxadustat: structure in first source
aromatic ether;
isoquinolines;
N-acylglycine
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
mgl-3196resmetirom: a thyroid hormone receptor-beta agonist